A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02) (ASCENT-J02)
The primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose (RP2D) of SG in Japanese participants with advance solid tumors. Phase 2: Evaluate the safety and efficacy of SG in Japanese participants with metastatic triple-negative breast cancer (mTNBC), hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC), and metastatic urothelial cancer (mUC).
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
Gender
N/A
Date
October 2021 - May 2026
Study Type
Interventional
Study Phase
Phase 1, Phase 2
Product
Sacituzumab Govitecan-hziy
Aichi, Japan, 464-8681
Akita, Japan, 010-8543
Aoba-ku, Japan, 980-8574
Aomori, Japan, 036-8563
Asahi-ku, Japan, 241-8515
Bunkyo-ku, Japan, 113-8431
Chiba, Japan, 260-8717
Chiba, Japan, 277-8577
Chuo-ku, Japan, 260-8717
Chuo-ku, Japan, 540-0006
Chuo-ku, Japan, 541-8567
Ehime, Japan, 791-0245
Ehime, Japan, 791-0280
Hyogo, Japan, 673-8558
Kagawa, Japan, 761-0793
Kanagawa, Japan, 259-1193
Koto, Japan, 135-8550
Kumamoto- shi, Japan, 860-8556
Minami-ku, Japan, 734-8551
Nara, Japan, 634-8522
Nishinomiya-shi, Japan, 663-8501
Okayama, Japan, 700-8558
Osakasayama-shi, Japan, 589-8511
Osaka, Japan, 545-0051
Osaka, Japan, 565-0871
Osaka, Japan, 577-8502
Saitama, Japan, 350-1298
Sakyo-ku, Japan, 606-8507
Sapporo, Japan, 003-0804
Shinjuku-ku, Japan, 162-8655
Tokyo, Japan, 104-0045
Tokyo, Japan, 113-8519
Tokyo, Japan, 142-8555
Tokyo, Japan, 1608582
Yamaguchi, Japan, 755-0046
Share Trial